{"result": "(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain, where the Escuela Nacional de Sanidad is located, focusing on public health education and research.)\n##\n(\"entity\"<|>ESCUELA NACIONAL DE SANIDAD<|>ORGANIZATION<|>The Escuela Nacional de Sanidad is a Spanish institution dedicated to public health education and research, providing training and resources for health professionals.)\n##\n(\"entity\"<|>SEEN<|>ORGANIZATION<|>SEEN is an organization involved in the field of clinical nutrition, contributing to the development and dissemination of knowledge in this area.)\n##\n(\"entity\"<|>GRUPO AULA MÉDICA<|>ORGANIZATION<|>Grupo Aula Médica is a publishing group that focuses on medical education and the dissemination of knowledge in various health-related fields.)\n##\n(\"entity\"<|>NUTRICIÓN<|>EVENT<|>Nutrition refers to the process of providing or obtaining the food necessary for health and growth, particularly in clinical settings.)\n##\n(\"relationship\"<|>ESCUELA NACIONAL DE SANIDAD<|>MADRID<|>The Escuela Nacional de Sanidad is located in Madrid, serving as a key institution for public health education in the city.<|>8)\n##\n(\"relationship\"<|>SEEN<|>NUTRICIÓN<|>SEEN is involved in the field of nutrition, promoting research and education related to clinical nutrition practices.<|>7)\n##\n(\"relationship\"<|>GRUPO AULA MÉDICA<|>NUTRICIÓN<|>Grupo Aula Médica publishes materials related to nutrition, contributing to the education and knowledge in the field of clinical nutrition.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: . Nutr Hosp. 2012;27(1):198-204.\n13. Mira JJ, Rodríguez Marín J, Peset R, Ybarra J, Pérez-Jover V, Palazón I, et al. Causas de satisfacción y de insatisfacción en hospitales y atención primaria. Rev Calidad Asistencial 2002; 17: 273-83.\n14. Agra Varela Y. Seguridad del paciente y gestión del riesgo [Internet]. Madrid: Escuela Nacional de Sanidad; 2012 [consultado 18/01/2015]. Tema 14.9.\n---\n# Tema 58.\n## Metodología para el diseño y desarrollo de productos de nutrición clínica\n\nMilagros Pérez Rodríguez\nDirectora I+D-Calidad. VEGENAT, S.A.\n\nÁfrica Jiménez Jiménez\nResponsable I+D. VEGENAT, S.A.\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 911-924.\n\n1. Introducción: objetivo de las actividades de diseño y desarrollo en la industria\n2. Proceso de innovación\n3. Metodología para el diseño de productos de nutrición clínica\n4. Metodología para el desarrollo de productos de nutrición clínica\n5. Controles necesarios durante el desarrollo\n6. El proceso de escalado y su validación\n7. Controles de producto y estudios de vida útil\n8. Evaluación clínica de productos\n9. Preparación para la fase de comercialización y lanzamiento al mercado\n10. Resumen\n11. Bibliografía\n\n### 1. Introducción: objetivo de las actividades de diseño y desarrollo en la industria\n\nLa investigación y desarrollo constituye uno de los pilares fundamentales en los que se sustenta el crecimiento de cualquier organización. Los altos niveles de competencia, la internacionalización económica y la aparición de nuevas tecnologías son solo tres de los muchos factores que provocan la necesidad de implementar cambios en las organizaciones en general y dentro de la industria de la nutrición especializada, en particular, a través de la innovación en productos o procesos con el objetivo de la diferenciación, creación de valor y en resumidas cuentas la sostenibilidad y competitividad en el mercado.\n\nLa gestión del cambio no radica en implementar modelos que a la larga resultan ser pasajeros. Se debe observar el entorno y anticiparse a las tendencias del mercado para estar siempre a la vanguardia¹.\n\nInnovar es utilizar el conocimiento, y generarlo si es necesario, para crear productos, servicios o procesos que sean nuevos para la empresa o mejorar los ya existentes, consiguiendo con ello tener éxito; es decir, la innovación se traduce en la aplicación comercial de una idea. Para llevar a cabo la innovación es necesario el conocimiento y este se genera a través de la investigación y el desarrollo (I+D) que, según el Manual de Frascati² de 2015, se refiere a las actividades que comprenden el trabajo creativo llevado a cabo de forma sistemática para incrementar el volumen de conocimientos y el uso de esos conocimientos para crear nuevas aplicaciones desde la investigación básica al desarrollo experimental. Los objetivos de esta labor sistemática a través de una determinada metodología o procesos pueden estar focalizados hacia sostener mercados, diversificar y/o cambiar el modelo de negocio. Esta tarea no se centra específicamente dentro del área de I+D de una compañía, sino que es una labor de equipo donde deben entrar a formar parte todos los departamentos con el objetivo de priorizar y focalizar la estrategia en aquellas que se consideren las «mejores ideas» de cara a los resultados de la empresa.\n---\n912      BLOQUE: NUTRICIÓN Y ASPECTOS LEGALES\n\n## 2. Proceso de innovación\n\nLa innovación tiene un carácter estratégico que no debe ser dejado al azar, suerte o a una genialidad. A diferencia de la mejora continua, innovar implica tomar riesgos que se desenvuelven en un marco de mayor incertidumbre por lo que debe ser un proceso controlado de etapas secuenciales¹.\n\nPara iniciar la innovación es necesario generar una «buena idea». Se requiere para ello de un profundo conocimiento del entorno (sector, mercado, consumidor, novedades científicas, tecnológicas, avances en envases, tecnologías de procesado, etc.). Junto a ello, la valoración de los gastos del proceso de desarrollo del nuevo producto es también imprescindible.\n\nUn buen análisis antes de iniciar el proceso de diseño y desarrollo ayudará a la identificación de aquellos productos que pueden tener mayor probabilidad de éxito equilibrando los costes. Este análisis consta de las siguientes etapas³⁻⁵:\n\na. Generación de ideas.\nb. Evaluación de oportunidades y selección de proyectos.\nc. Diseño y desarrollo de productos: diseño básico; desarrollo detallado y prueba piloto; rediseño, escala semiindustrial, escala preserie y producción; y finalmente, comercialización.\n\n### a\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>VEGENAT, S.A.<|>ORGANIZATION<|>VEGENAT, S.A. is a company involved in the research and development of clinical nutrition products, focusing on innovation and quality in the industry.)\n##\n(\"entity\"<|>MILAGROS PÉREZ RODRÍGUEZ<|>PERSON<|>Milagros Pérez Rodríguez is the Director of R&D and Quality at VEGENAT, S.A., overseeing the development of nutrition products.)\n##\n(\"entity\"<|>ÁFRICA JIMÉNEZ JIMÉNEZ<|>PERSON<|>África Jiménez Jiménez is the R&D Manager at VEGENAT, S.A., responsible for research and development activities.)\n##\n(\"entity\"<|>NUTRICIÓN CLÍNICA<|>EVENT<|>Clinical nutrition refers to the specialized field focused on dietary management and nutritional support for patients.)\n##\n(\"entity\"<|>I+D<|>EVENT<|>Research and Development (I+D) is a systematic creative work aimed at increasing knowledge and creating new applications in various fields, including nutrition.)\n##\n(\"relationship\"<|>MILAGROS PÉREZ RODRÍGUEZ<|>VEGENAT, S.A.<|>Milagros Pérez Rodríguez is the Director of R&D and Quality at VEGENAT, S.A., leading the company's innovation efforts in clinical nutrition.<|>9)\n##\n(\"relationship\"<|>ÁFRICA JIMÉNEZ JIMÉNEZ<|>VEGENAT, S.A.<|>África Jiménez Jiménez is the R&D Manager at VEGENAT, S.A., working under Milagros Pérez Rodríguez in the development of nutrition products.<|>8)\n##\n(\"relationship\"<|>MILAGROS PÉREZ RODRÍGUEZ<|>NUTRICIÓN CLÍNICA<|>Milagros Pérez Rodríguez's work in R&D at VEGENAT, S.A. contributes to advancements in clinical nutrition.<|>7)\n##\n(\"relationship\"<|>ÁFRICA JIMÉNEZ JIMÉNEZ<|>NUTRICIÓN CLÍNICA<|>África Jiménez Jiménez's role in R&D at VEGENAT, S.A. is focused on developing products for clinical nutrition.<|>7)\n##\n(\"relationship\"<|>I+D<|>VEGENAT, S.A.<|>VEGENAT, S.A. engages in research and development (I+D) to innovate and improve clinical nutrition products.<|>8)\n<|COMPLETE|>"}]}